Cantor Fitzgerald Initiates Coverage On AVITA Medical with Overweight Rating, Announces Price Target of $23
Portfolio Pulse from richadhand@benzinga.com
Cantor Fitzgerald analyst Ross Osborn initiates coverage on AVITA Medical (NASDAQ:RCEL) with an Overweight rating and a price target of $23.
June 27, 2023 | 10:28 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AVITA Medical receives an Overweight rating and a $23 price target from Cantor Fitzgerald analyst Ross Osborn.
Cantor Fitzgerald's initiation of coverage on AVITA Medical with an Overweight rating and a price target of $23 indicates a positive outlook for the stock. This news is likely to attract investors and drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100